FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2549580878> ?p ?o ?g. }

• W2549580878 endingPage "28" @default.
• W2549580878 startingPage "28" @default.
• W2549580878 abstract "Abstract Introduction: Elotuzumab is an immunostimulatory monoclonal antibody (mAb) that recognizes Signaling Lymphocytic Activation Molecule F7 (SLAMF7), a protein highly expressed by myeloma and natural killer cells. Elotuzumab has a dual mechanism of action, directly activating natural killer cells and initiating antibody-dependent cell-mediated cytotoxicity targeted against myeloma cells, with minimal effect on normal tissues. In the 2-year progression-free survival (PFS) interim analysis of ELOQUENT-2, a Phase 3 study (NCT01239797) comparing elotuzumab plus lenalidomide/dexamethasone (ELd) with lenalidomide/dexamethasone (Ld), ELd resulted in a significant 30% reduction in the risk of disease progression or death vs Ld (hazard ratio 0.70 [95% CI 0.57, 0.85]; p=0.0004). Overall response rate (ORR) was 79% (95% CI 74, 83) in the ELd arm vs 66% (95% CI 60, 71) in the Ld arm (p=0.0002). Furthermore, the addition of elotuzumab to Ld was well tolerated, with minimal added toxicity.1 Elotuzumab's immunotherapeutic effect induces effective therapeutic outcomes and represents an important approach to treating multiple myeloma (MM). Here we present extended 3-year follow-up data. Methods: As previously described,1 patients (pts) with relapsed/refractory MM (RRMM) and 1-3 prior therapies were randomized 1:1 to ELd or Ld in 28-day cycles until disease progression or unacceptable toxicity. Primary endpoints were PFS and ORR. Secondary and other endpoints included overall survival (OS) and health-related quality of life. Post hoc analyses assessed Worst Pain using the Brief Pain Inventory-Short Form (BPI-SF); data were collected at screening, on Day 1 of each 28-day cycle, and at the end of treatment. Sustained improvement in pain was defined by a decrease of ≥3 points for ≥2 consecutive treatment cycles. Results: In total, 646 RRMM pts were randomized (321 to ELd, 325 to Ld). Baseline demographic factors included: median age 66 years (20% ≥75 years old); 32% of pts had del17p and 10% had t(4;14); median prior number of therapies was 2; and 35% of pts were refractory to their last therapy. At data cut-off (16 May 2015), 29% of pts treated with ELd vs 15% of pts treated with Ld remained on study therapy; discontinuation was mainly due to disease progression (46% in ELd arm, 51% in Ld arm). Grade 3-4 adverse events in ≥15% of pts included lymphopenia (78% in ELd arm, 49% in Ld arm), neutropenia (35% in ELd arm, 44% in Ld arm), anemia (20% in ELd arm, 21% in Ld arm), and thrombocytopenia (21% in ELd arm, 20% in Ld arm). Infections (any grade) occurred in 83% of pts in the ELd arm and 75% in the Ld arm. Exposure-adjusted infection rates (incidence rate/100 person-years of exposure) were 196 and 193 in the ELd and Ld arms, respectively. Infusion reactions (mostly Grade 1-2) occurred in 11% of pts treated with ELd. In total, there were 263 deaths during treatment follow-up (123 [47%] in ELd arm, 140 [53%] in Ld arm); 62% of the required 427 deaths for the OS final analysis. With regard to patient-reported pain (BPI-SF), sustained improvement in Worst Pain was observed in pts with ORR, with more pts demonstrating sustained improvement in the ELd arm (n=74) vs the Ld arm (n=56). 3-year PFS and the interim analysis of OS will be presented. Conclusions: Elotuzumab is the first immunostimulatory mAb for the treatment of MM to demonstrate a statistically significant and clinically relevant improvement in efficacy with minimal added toxicity.1 The addition of elotuzumab to Ld led to an effective and durable benefit, representing a novel approach to treating MM. The updated safety and tolerability data reported were consistent with previous findings, confirming that there are minimal incremental toxicities associated with the addition of elotuzumab. A greater proportion of ELd pts vs Ld pts with an ORR had improvement in BPI-SF Worst Pain. Three-year PFS data and the interim analysis of OS will be presented, providing insight into the long-term benefits of ELd therapy. Reference: 1. Lonial S et al. N Engl J Med 2015; Jun 2 [Epub ahead of print]. Study funding: Study funded by Bristol-Myers Squibb and AbbVie Biotherapeutics. Writing assistance was provided by S Addison, PhD, at Caudex and funded by Bristol-Myers Squibb. Disclosures Dimopoulos: Genesis: Honoraria; Celgene: Honoraria; Amgen: Honoraria; Novartis: Honoraria; Janssen: Honoraria; Onyx: Honoraria; Janssen-Cilag: Honoraria. Off Label Use: Elotuzumab is an investigational agent being studied for the treatment of multiple myeloma. . Lonial:Novartis: Consultancy, Research Funding; Millennium: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Onyx: Consultancy, Research Funding; Celgene: Consultancy, Research Funding. White:Millennium: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Janssen-Cilag: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Consultancy, Honoraria. Moreau:Millennium: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees. Palumbo:Array BioPharma: Honoraria; Janssen-Cilag: Consultancy, Honoraria; Sanofi-Aventis: Honoraria; Genmab A/S: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Millennium: Consultancy, Honoraria; Onyx: Consultancy, Honoraria; Amgen: Consultancy, Honoraria. San Miguel:Novartis: Honoraria; Sanofi-Aventis: Honoraria; Janssen-Cilag: Honoraria; Celgene: Honoraria; Onyx: Honoraria; Bristol-Myers Squibb: Honoraria; Millennium: Honoraria. Shpilberg:Millennium Takeda: Consultancy; Gilead: Consultancy. Spicka:Janssen-Cilag: Consultancy; Celgene: Consultancy, Research Funding; Amgen: Consultancy; Bristol-Myers Squibb: Consultancy. Mateos:Onyx: Consultancy; Janssen-Cilag: Consultancy, Honoraria; Takeda: Consultancy; Celgene: Consultancy, Honoraria. Reece:Amgen: Honoraria; Novartis: Honoraria, Research Funding; Otsuka: Research Funding; Janssen-Cilag: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Lundbeck: Honoraria; Millennium Takeda: Research Funding; Bristol-Myers Squibb: Research Funding; Onyx: Consultancy; Merck: Research Funding. Beksac:Novartis: Consultancy; Takeda: Consultancy, Honoraria; Amgen: Honoraria, Speakers Bureau; Janssen-Cilag: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau; Bristol-Myers Squibb: Consultancy. Bleickhardt:Bristol-Myers Squibb: Employment. Poulart:Bristol-Myers Squibb: Employment. Katz:Bristol-Myers Squibb: Employment. Singhal:Abbvie: Employment. Richardson:Celgene: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Millennium Takeda: Membership on an entity's Board of Directors or advisory committees; Johnson & Johnson: Membership on an entity's Board of Directors or advisory committees." @default.
• W2549580878 created "2016-11-30" @default.
• W2549580878 creator A5004781025 @default.
• W2549580878 creator A5013047847 @default.
• W2549580878 creator A5018685925 @default.
• W2549580878 creator A5020123690 @default.
• W2549580878 creator A5023276777 @default.
• W2549580878 creator A5023571997 @default.
• W2549580878 creator A5024642496 @default.
• W2549580878 creator A5029159537 @default.
• W2549580878 creator A5030524608 @default.
• W2549580878 creator A5032464400 @default.
• W2549580878 creator A5043490010 @default.
• W2549580878 creator A5043526996 @default.
• W2549580878 creator A5045434968 @default.
• W2549580878 creator A5050479677 @default.
• W2549580878 creator A5058355502 @default.
• W2549580878 creator A5059967673 @default.
• W2549580878 creator A5062322697 @default.
• W2549580878 creator A5067684052 @default.
• W2549580878 creator A5069449708 @default.
• W2549580878 creator A5073964632 @default.
• W2549580878 creator A5080776694 @default.
• W2549580878 date "2015-12-03" @default.
• W2549580878 modified "2023-10-11" @default.
• W2549580878 title "Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up" @default.
• W2549580878 doi "https://doi.org/10.1182/blood.v126.23.28.28" @default.
• W2549580878 hasPublicationYear "2015" @default.
• W2549580878 type Work @default.
• W2549580878 sameAs 2549580878 @default.
• W2549580878 citedByCount "23" @default.
• W2549580878 countsByYear W25495808782016 @default.
• W2549580878 countsByYear W25495808782017 @default.
• W2549580878 countsByYear W25495808782018 @default.
• W2549580878 countsByYear W25495808782019 @default.
• W2549580878 countsByYear W25495808782020 @default.
• W2549580878 crossrefType "journal-article" @default.
• W2549580878 hasAuthorship W2549580878A5004781025 @default.
• W2549580878 hasAuthorship W2549580878A5013047847 @default.
• W2549580878 hasAuthorship W2549580878A5018685925 @default.
• W2549580878 hasAuthorship W2549580878A5020123690 @default.
• W2549580878 hasAuthorship W2549580878A5023276777 @default.
• W2549580878 hasAuthorship W2549580878A5023571997 @default.
• W2549580878 hasAuthorship W2549580878A5024642496 @default.
• W2549580878 hasAuthorship W2549580878A5029159537 @default.
• W2549580878 hasAuthorship W2549580878A5030524608 @default.
• W2549580878 hasAuthorship W2549580878A5032464400 @default.
• W2549580878 hasAuthorship W2549580878A5043490010 @default.
• W2549580878 hasAuthorship W2549580878A5043526996 @default.
• W2549580878 hasAuthorship W2549580878A5045434968 @default.
• W2549580878 hasAuthorship W2549580878A5050479677 @default.
• W2549580878 hasAuthorship W2549580878A5058355502 @default.
• W2549580878 hasAuthorship W2549580878A5059967673 @default.
• W2549580878 hasAuthorship W2549580878A5062322697 @default.
• W2549580878 hasAuthorship W2549580878A5067684052 @default.
• W2549580878 hasAuthorship W2549580878A5069449708 @default.
• W2549580878 hasAuthorship W2549580878A5073964632 @default.
• W2549580878 hasAuthorship W2549580878A5080776694 @default.
• W2549580878 hasConcept C126322002 @default.
• W2549580878 hasConcept C142424586 @default.
• W2549580878 hasConcept C143998085 @default.
• W2549580878 hasConcept C2776063141 @default.
• W2549580878 hasConcept C2776364478 @default.
• W2549580878 hasConcept C2780401358 @default.
• W2549580878 hasConcept C2781119759 @default.
• W2549580878 hasConcept C31760486 @default.
• W2549580878 hasConcept C535046627 @default.
• W2549580878 hasConcept C71924100 @default.
• W2549580878 hasConcept C86803240 @default.
• W2549580878 hasConcept C87355193 @default.
• W2549580878 hasConceptScore W2549580878C126322002 @default.
• W2549580878 hasConceptScore W2549580878C142424586 @default.
• W2549580878 hasConceptScore W2549580878C143998085 @default.
• W2549580878 hasConceptScore W2549580878C2776063141 @default.
• W2549580878 hasConceptScore W2549580878C2776364478 @default.
• W2549580878 hasConceptScore W2549580878C2780401358 @default.
• W2549580878 hasConceptScore W2549580878C2781119759 @default.
• W2549580878 hasConceptScore W2549580878C31760486 @default.
• W2549580878 hasConceptScore W2549580878C535046627 @default.
• W2549580878 hasConceptScore W2549580878C71924100 @default.
• W2549580878 hasConceptScore W2549580878C86803240 @default.
• W2549580878 hasConceptScore W2549580878C87355193 @default.
• W2549580878 hasIssue "23" @default.
• W2549580878 hasLocation W25495808781 @default.
• W2549580878 hasOpenAccess W2549580878 @default.
• W2549580878 hasPrimaryLocation W25495808781 @default.
• W2549580878 hasRelatedWork W2192430028 @default.
• W2549580878 hasRelatedWork W2510398184 @default.
• W2549580878 hasRelatedWork W2531713994 @default.
• W2549580878 hasRelatedWork W2890977830 @default.
• W2549580878 hasRelatedWork W2947874495 @default.
• W2549580878 hasRelatedWork W3095177954 @default.
• W2549580878 hasRelatedWork W3121407702 @default.
• W2549580878 hasRelatedWork W4200325876 @default.
• W2549580878 hasRelatedWork W4310106503 @default.
• W2549580878 hasRelatedWork W4377220744 @default.
• W2549580878 hasVolume "126" @default.
• W2549580878 isParatext "false" @default.

• next